Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Pulmonary Arterial Hypertension Causes and Pathophysiology

Introduction to PAH

  • Pulmonary arterial hypertension (PAH) is caused by a complex interplay of genetic factors, molecular abnormalities, and environmental exposures that lead to vascular remodeling, vasoconstriction, thrombosis, and inflammation of the pulmonary arteries, resulting in increased pulmonary vascular resistance and ultimately right heart failure, as stated by the American College of Cardiology 1, 2

Pathophysiological Mechanisms

  • Endothelial dysfunction is characterized by increased production of vasoconstrictors and decreased production of vasodilators, creating an imbalance that promotes vasoconstriction and cell proliferation, according to the European Heart Journal 3
  • Vascular remodeling involves intimal hyperplasia, medial hypertrophy, adventitial proliferation, and plexiform arteriopathy that progressively narrows pulmonary vessel lumens, as reported by the American College of Cardiology 1, 2
  • Thrombosis in situ is associated with elevated levels of fibrinopeptide A and plasminogen activator inhibitor-1 with reduced tissue plasminogen activator, contributing to a procoagulant state, as stated by the American College of Cardiology 1
  • Altered cellular phenotype is characterized by decreased ratio of apoptosis/proliferation in pulmonary artery smooth muscle cells (PASMCs) leading to excessive proliferation, according to the American College of Cardiology 1

Specific Causes by Category

Genetic Factors

  • BMPR2 mutations are present in 75% of familial PAH cases and up to 25% of idiopathic PAH cases, causing loss of function in the SMAD signaling pathway that normally regulates vascular cell growth, as reported by the American College of Cardiology 1, 4
  • Activin-like kinase 1 (ALK1) mutations are found in patients with hereditary hemorrhagic telangiectasia and PAH, affecting SMAD-dependent signaling, according to the American College of Cardiology 1
  • Other genetic polymorphisms, such as serotonin transporter gene, nitric oxide synthase, and carbamyl-phosphate synthase gene, may act as additional triggers, as stated by the European Heart Journal 5

Associated Medical Conditions

  • Connective tissue diseases, particularly the limited cutaneous form of systemic sclerosis (CREST syndrome), systemic lupus erythematosus, mixed connective tissue disease, and rheumatoid arthritis, are associated with PAH, as reported by the American College of Cardiology 4
  • Congenital heart disease, such as left-to-right shunts, can cause increased pulmonary blood flow and pressure, potentially leading to Eisenmenger syndrome, according to the American College of Cardiology 4, 6
  • HIV infection occurs in approximately 0.5% of HIV-infected individuals, independent of CD4 count but related to duration of infection, as stated by the American College of Cardiology 4
  • Portal hypertension is associated with portopulmonary hypertension, as reported by the European Respiratory Journal 7
  • Hematological disorders, such as chronic hemolytic anemias, myeloproliferative disorders, and post-splenectomy states, are associated with PAH, according to the European Respiratory Journal 7

Drug and Toxin Exposure

  • Anorexigens, such as aminorex, fenfluramine, and dexfenfluramine, have been linked to PAH development, as reported by the American College of Cardiology 4
  • Other substances, such as toxic rapeseed oil, amphetamines, L-tryptophan, and certain chemotherapeutic agents, may also contribute to PAH, according to the American College of Cardiology 8

Molecular Abnormalities

  • Serotonin abnormalities, including elevated plasma serotonin levels and platelets depleted of serotonin, are associated with PAH, as stated by the American College of Cardiology 1
  • Potassium channel dysfunction, including downregulation of voltage-gated potassium channels (Kv1.5), leads to membrane depolarization and increased intracellular calcium, as reported by the American College of Cardiology 1, 4
  • Prostacyclin and thromboxane A2 imbalance, characterized by reduced prostacyclin and increased thromboxane A2, contributes to PAH, according to the American College of Cardiology 1, 3

Clinical Implications

  • PAH can develop years to decades after closure of congenital heart defects, suggesting ongoing pathological processes, as stated by the American College of Cardiology 6
  • Severity ranges from mild pressure elevation to profound systemic or suprasystemic levels of pulmonary artery pressure, according to the American College of Cardiology 6
  • When an anatomic defect allowing shunting is present, shunt reversal and cyanosis may develop as pulmonary resistance rises above systemic resistance (Eisenmenger syndrome), as reported by the American College of Cardiology 6

Diagnostic Considerations

  • Patients with septal or great artery shunts should undergo periodic screening for pulmonary hypertension with echocardiography, as recommended by the American College of Cardiology 9
  • Cardiac catheterization is recommended for definitive diagnosis and hemodynamic assessment in patients with clinical symptoms, signs, or echocardiographic findings suggestive of pulmonary hypertension, according to the American College of Cardiology 6, 9
  • BNP, chest x-ray, 6-minute walk test, and cardiac catheterization are useful for initial and follow-up evaluation, as stated by the American College of Cardiology 9

Important Distinctions

  • PAH (WHO Group 1) must be distinguished from other forms of pulmonary hypertension, including PH due to left heart disease (Group 2), PH due to lung diseases and/or hypoxemia (Group 3), chronic thromboembolic PH (Group 4), and PH with unclear or multifactorial mechanisms (Group 5), as reported by the European Respiratory Journal 7 and the European Heart Journal 3

Pulmonary Arterial Hypertension Causes and Classification

Classification of PAH (WHO Group 1)

  • The American College of Cardiology reports that idiopathic PAH occurs without identifiable causes with a prevalence of approximately 6 per million, and has a female/male ratio of 1.7:1 with a mean age at diagnosis of 37 years 10
  • The American College of Cardiology states that heritable/familial PAH accounts for 6-10% of PAH cases, and is associated with genetic mutations, including BMPR2 mutations in 50-90% of familial cases and up to 25% of idiopathic PAH cases 10
  • The American College of Cardiology notes that fenfluramine-related PAH shows BMPR2 mutations in approximately 15% of cases 10
  • The European Respiratory Journal reports that the risk of portopulmonary hypertension increases with severity of liver disease 11
  • The European Respiratory Journal states that schistosomiasis is an important cause of PAH in endemic regions 11, 12
  • The European Respiratory Journal notes that chronic hemolytic anemia, including sickle cell disease, thalassemia, and hereditary spherocytosis, is associated with PAH 11
  • The European Respiratory Journal reports that persistent pulmonary hypertension of the newborn is caused by failure of normal circulatory transition at birth 11
  • The European Respiratory Journal distinguishes PAH (WHO Group 1) from other forms of pulmonary hypertension, including Group 2 (PH due to left heart disease), Group 3 (PH due to lung diseases and/or hypoxemia), Group 4 (chronic thromboembolic PH), and Group 5 (PH with unclear or multifactorial mechanisms) 11

REFERENCES